
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8545392/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Two Cultures at Cambridge. European Review, 2019, 27, 46-53.	0.7	Ο
2	John Gordon—A greatly undervalued complement pioneer. Immunobiology, 2018, 223, 524-525.	1.9	0
3	Looking back on the alternative complement pathway. Immunobiology, 2018, 223, 519-523.	1.9	30
4	Experimental confirmation of the C3 tickover hypothesis by studies with an Ab (S77) that inhibits tickover in whole serum. FASEB Journal, 2018, 32, 123-129.	0.5	29
5	Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2018, 391, 1108-1120.	13.7	153
6	Lectin pathway effector enzyme mannanâ€binding lectinâ€associated serine proteaseâ€2 can activate native complement C3 in absence of C4 and/or C2. FASEB Journal, 2017, 31, 2210-2219.	0.5	43
7	Editorial (Thematic Issue: The Urgent Need to Reform the Present System of Medicines' Regulation). Reviews on Recent Clinical Trials, 2015, 10, 2-4.	0.8	Ο
8	A More Radical Solution. Reviews on Recent Clinical Trials, 2015, 10, 25-27.	0.8	1
9	Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle <i>in vitro</i> . Clinical and Experimental Immunology, 2015, 181, 314-322.	2.6	28
10	Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype. Clinical and Experimental Immunology, 2015, 183, 150-156.	2.6	8
11	Traditional passive immune therapy for emerging Ebola infection. Emerging Microbes and Infections, 2014, 3, 81-2.	6.5	Ο
12	Low-dose recombinant properdin provides substantial protection against <i>Streptococcus pneumoniae</i> and <i>Neisseria meningitidis</i> infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5301-5306.	7.1	48
13	Ethics Evolve. European Review, 2013, 21, S109-S113.	0.7	2
14	The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 1179-1189.	0.5	16
15	The Grandmother Effect. Gerontology, 2011, 57, 375-377.	2.8	13
16	Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK. Lancet, The, 2011, 377, 1149.	13.7	4
17	Preparing serum for functional complement assays. Journal of Immunological Methods, 2010, 352, 195-197.	1.4	62
18	Genetic and Cultural Evolution: From Fossils to Proteins, and from Behaviour to Ethics. European Review, 2010, 18, 297-309.	0.7	7

#	Article	IF	CITATIONS
19	Religion—An evolutionary adaptation. FASEB Journal, 2010, 24, 1301-1307.	0.5	4
20	An open letter to the health secretary: how to really save money on the NHS. BMJ: British Medical Journal, 2010, 341, c5618-c5618.	2.3	0
21	Robert Royston Amos (Robin) Coombs. 9 January 1921 — 25 January 2006. Biographical Memoirs of Fellows of the Royal Society, 2009, 55, 45-58.	0.1	1
22	Taking Complement to the Clinic – has the Time Finally Come?. Scandinavian Journal of Immunology, 2009, 69, 471-478.	2.7	31
23	Anti-infective antibodies—Reviving an old paradigm. Vaccine, 2009, 27, G33-G37.	3.8	4
24	The Amplification Loop of the Complement Pathways. Advances in Immunology, 2009, 104, 115-149.	2.2	187
25	A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates. Clinical and Experimental Immunology, 2008, 82, 200-207.	2.6	6
26	Cytostasis of different tumours by a murine PPD-reactive CD4+ T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically. Clinical and Experimental Immunology, 2008, 82, 208-213.	2.6	9
27	Bispecific antibody: a tool for diagnosis and treatment of disease. Clinical and Experimental Immunology, 2008, 79, 315-321.	2.6	34
28	Peptide inhibitors of C3 breakdown. Clinical and Experimental Immunology, 2008, 79, 454-458.	2.6	1
29	The complement-inhibiting protein, Protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clinical and Experimental Immunology, 2008, 83, 251-256.	2.6	39
30	The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clinical and Experimental Immunology, 2008, 84, 1-8.	2.6	191
31	Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clinical and Experimental Immunology, 2008, 87, 415-421.	2.6	29
32	An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis. Clinical and Experimental Immunology, 2008, 87, 144-149.	2.6	24
33	C7 M/N protein polymorphism typing applied to inherited deficiencies of human complement proteins C6 and C7. Clinical and Experimental Immunology, 2008, 89, 485-489.	2.6	11
34	C6 haplotypes: associations of a Dde I site polymorphism to complement deficiency genes and the Msp I restriction fragment length polymorphism (RFLP). Clinical and Experimental Immunology, 2008, 95, 351-356.	2.6	8
35	A systematic study of neutrophil degranulation and respiratory burst <i>in vitro</i> by defined immune complexes. Clinical and Experimental Immunology, 2008, 101, 507-514.	2.6	40
36	The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clinical and Experimental Immunology, 2008, 99, 160-167.	2.6	240

#	Article	IF	CITATIONS
37	Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities. Microbes and Infection, 2007, 9, 300-307.	1.9	20
38	Statistical issues in first-in-man studies. Journal of the Royal Statistical Society Series A: Statistics in Society, 2007, 170, 517-579.	1.1	40
39	The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus. Arthritis Research and Therapy, 2006, 8, R68.	3.5	14
40	Inhibition of antimicrobial peptides by group A streptococci: SIC and DRS. Biochemical Society Transactions, 2006, 34, 273.	3.4	10
41	The complement system in renal diseases. , 2006, , 1-18.		1
42	Complement before molecular biology. Molecular Immunology, 2006, 43, 496-508.	2.2	31
43	Crystal-ball gazing??the future of immunological research viewed from the cutting edge. Clinical and Experimental Immunology, 2006, 147, 061120065600010-???.	2.6	10
44	Attribution of the Various Inhibitory Actions of the Streptococcal Inhibitor of Complement (SIC) to Regions within the Molecule. Journal of Biological Chemistry, 2005, 280, 20120-20125.	3.4	32
45	The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins. Immunology, 2004, 111, 444-452.	4.4	63
46	Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics. Current Pharmaceutical Design, 2004, 10, 2891-2905.	1.9	64
47	Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex. Immunology Letters, 2003, 90, 209-213.	2.5	15
48	Henry Kunkel. Lupus, 2003, 12, 200-201.	1.6	0
49	Consent and confidentiality–where are the limits? An introduction. Journal of Medical Ethics, 2003, 29, 2-3.	1.8	13
50	Lupus and desoxyribonuclease. Lupus, 2003, 12, 202-206.	1.6	25
51	Streptococcal Inhibitor of Complement Inhibits Two Additional Components of the Mucosal Innate Immune System: Secretory Leukocyte Proteinase Inhibitor and Lysozyme. Infection and Immunity, 2002, 70, 4908-4916.	2.2	87
52	Microbial subversion of the immune response. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8461-8462.	7.1	33
53	Subversion of the innate immune response by micro-organisms. Annals of the Rheumatic Diseases, 2002, 61, 8ii-12.	0.9	16
54	The risk to the United Kingdom population of zinc cadmium sulfide dispersion by the Ministry of Defence during the "cold war". Occupational and Environmental Medicine, 2002, 59, 13-17.	2.8	1

#	Article	IF	CITATIONS
55	Stem cell therapy: medical advance or moral challenge?. Comptes Rendus - Biologies, 2002, 325, 1049-1051.	0.2	1
56	Stem cell research—why is it regarded as a threat?. EMBO Reports, 2001, 2, 165-168.	4.5	10
57	Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology, 2001, 103, 390-398.	4.4	106
58	Antibodies raised to short synthetic peptides with sequences derived from HIV-1 SF2 gp120 can both neutralize and enhance HIV-1 SF13: A later variant isolated from the same host. Journal of Medical Virology, 2001, 64, 207-216.	5.0	11
59	Systemic Lupus Erythematosus, Complement Deficiency, and Apoptosis. Advances in Immunology, 2001, 76, 227-324.	2.2	461
60	Interaction between Host Complement and Mosquito-Midgut-Stage Plasmodium berghei. Infection and Immunity, 2001, 69, 5064-5071.	2.2	62
61	Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross-linking of Fcα receptors (Fcα R) with a monoclonal antibody, MIP8a. Clinical and Experimental Immunology, 2000, 121, 106-111.	2.6	14
62	Anti-DNA antibodies in the urine of lupus nephritis patients. Nephrology Dialysis Transplantation, 1999, 14, 1418-1424.	0.7	11
63	Comparison of C1q-receptors on rat microglia and peritoneal macrophages. Journal of Neuroimmunology, 1999, 94, 74-81.	2.3	9
64	GM food debate. Lancet, The, 1999, 354, 1726.	13.7	4
65	Health risks of genetically modified foods. Lancet, The, 1999, 354, 69.	13.7	13
66	Britain's Academy of Medical Sciences has been busy in recent months. BMJ: British Medical Journal, 1999, 318, 1624-1624.	2.3	0
67	Microbial immunology: A new mechanism for immune subversion. Current Biology, 1998, 8, R99-R101.	3.9	11
68	It's what not where you publish that matters. Astronomy and Geophysics, 1998, 39, 3.9-3.9.	0.2	0
69	Public Health and Bioethics. Journal of Medicine and Philosophy, 1998, 23, 297-302.	0.8	12
70	Neuronal protection of oligodendrocytes from antibody-independent complement lysis. NeuroReport, 1998, 9, 927-932.	1.2	7
71	Herpes virus saimiri CD59 - baculovirus expression and characterisation of complement inhibitory activity. Biochemical Society Transactions, 1997, 25, 354S-354S.	3.4	14
72	Complement in IgA immune-complex-induced neutrophil activation. Biochemical Society Transactions, 1997, 25, 462-466.	3.4	3

#	Article	IF	CITATIONS
73	Complement and immunity to viruses. Immunological Reviews, 1997, 159, 69-77.	6.0	48
74	Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clinical and Experimental Immunology, 1997, 108, 220-226.	2.6	104
75	Difficulties in the ascertainment of C9 deficiency: lessons to be drawn from a compound heterozygote C9-deficient subject. Clinical and Experimental Immunology, 1997, 108, 500-506.	2.6	8
76	Neutrophil Fcl ³ and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. European Journal of Immunology, 1997, 27, 2514-2523.	2.9	56
77	Complement-Induced Release of Monocyte Chemotactic Protein-1 From Human Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 673-677.	2.4	93
78	CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients. Clinical and Experimental Immunology, 1996, 105, 497-503.	2.6	30
79	The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clinical and Experimental Immunology, 1996, 106, 243-252.	2.6	138
80	The in vivo destruction of antigen-a tool for probing and modulating an autoimmune response. Clinical and Experimental Immunology, 1996, 106, 187-189.	2.6	15
81	How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion. Immunology, 1996, 88, 407-411.	4.4	25
82	Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells Journal of Clinical Investigation, 1996, 98, 2819-2826.	8.2	227
83	Neutrophil lactoferrin release induced by IgA immune complexes can be mediated either by Fc alpha receptors or by complement receptors through different pathways. Journal of Immunology, 1996, 156, 2599-606.	0.8	14
84	Lymphocytotropic Strains of HIV Type 1 When Complexed with Enhancing Antibodies Can Infect Macrophages via Fcl³RIII, Independently of CD4. AIDS Research and Human Retroviruses, 1995, 11, 343-352.	1.1	35
85	Complement component C6 and C7 haplotypes associated with deficiencies of C6. Annals of Human Genetics, 1995, 59, 183-195.	0.8	12
86	Study of the in vitro activation of the complement alternative pathway by Echinococcus granulosus hydatid cyst fluid. Parasite Immunology, 1995, 17, 245-251.	1.5	18
87	Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6 Journal of Clinical Investigation, 1995, 95, 1877-1883.	8.2	51
88	Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59 Journal of Experimental Medicine, 1994, 179, 1625-1636.	8.5	71
89	Introduction. Seminars in Immunopathology, 1994, 15, 303-306.	4.0	1
90	The profiles of interleukin (IL)-2, IL-6, and interferon-gamma production by peripheral blood mononuclear cells from house-dust-mite-allergic patients: a role for IL-6 in allergic disease. Allergy: European Journal of Allergy and Clinical Immunology, 1994, 49, 751-759.	5.7	20

#	Article	IF	CITATIONS
91	A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom. Allergy: European Journal of Allergy and Clinical Immunology, 1994, 49, 272-280.	5.7	34
92	Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure, 1994, 2, 185-199.	3.3	178
93	A NOVEL HUMAN COMPLEMENT COMPONENT C7 PHENOTYPE DETECTED IN SOUTH AFRICA AND PROPOSED DESIGNATION OF THE ALLELE AS C7*10. International Journal of Immunogenetics, 1994, 21, 181-187.	1.2	2
94	Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. Journal of Virology, 1994, 68, 8001-8007.	3.4	239
95	Construction, expression and functional analysis of a glycolipid-linked form of CR1. European Journal of Immunology, 1993, 23, 2346-2352.	2.9	10
96	Sequenceâ€specific. Protein Science, 1993, 2, 2015-2027.	7.6	30
97	Membrane defence against complement lysis: The structure and biological properties of CD59. Immunologic Research, 1993, 12, 258-75.	2.9	151
98	Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. Journal of General Virology, 1993, 74, 2609-2617.	2.9	20
99	Complement-mediated adipocyte lysis by nephritic factor sera Journal of Experimental Medicine, 1993, 177, 1827-1831.	8.5	119
100	Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. Journal of General Virology, 1992, 73, 1099-1106.	2.9	17
101	Mechanisms of oligodendrocyte interaction with normal human serum - defining the role of complement. Journal of the Neurological Sciences, 1992, 108, 65-72.	0.6	20
102	Glycosylation Governs the Binding of Antipeptide Antibodies to Regions of Hypervariable Amino Acid Sequence within Recombinant gp120 of Human Immunodeficiency Virus Type 1. Journal of General Virology, 1990, 71, 2889-2898.	2.9	69
103	The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens. Journal of General Virology, 1990, 71, 1975-1983.	2.9	31
104	Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology, 1990, 71, 1-9.	4.4	419
105	CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells Journal of Experimental Medicine, 1989, 170, 637-654.	8.5	618
106	The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation. European Journal of Immunology, 1988, 18, 1217-1222.	2.9	58
107	Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochemical Journal, 1988, 253, 667-675.	3.7	32

108 Resolution and analysis of †native' and †activated' properdin. Biochemical Journal, 1987, 243, 507-5173.7 63

#	Article	IF	CITATIONS
109	Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus. Arthritis and Rheumatism, 1987, 30, 961-966.	6.7	68
110	Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clinical and Experimental Immunology, 1987, 69, 501-7.	2.6	58
111	Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clinical and Experimental Immunology, 1985, 59, 547-54.	2.6	130
112	Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. Clinical and Experimental Immunology, 1985, 61, 1-8.	2.6	21
113	Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. Journal of Immunology, 1985, 134, 3307-15.	0.8	344
114	Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. Journal of Immunology, 1985, 135, 2005-14.	0.8	229
115	Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). European Journal of Immunology, 1984, 14, 236-243.	2.9	119
116	Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies Journal of Experimental Medicine, 1982, 156, 205-216.	8.5	214
117	Three rat monoclonal antibodies to human C3. Immunology, 1980, 41, 503-15.	4.4	82
118	The immunogloblin nature of nephritic factor (NeF). Clinical and Experimental Immunology, 1978, 32, 12-24.	2.6	70
119	Identification of Ss protein as murine C4. Nature, 1975, 258, 242-243.	27.8	101
120	Lymphosarcoma, Cold Urticaria, IgG ₁ Monoclonal Cryoglobulin and Complement Abnormalities. Scandinavian Journal of Haematology, 1975, 15, 22-26.	0.0	27
121	Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency Journal of Clinical Investigation, 1975, 55, 668-672.	8.2	64
122	The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clinical and Experimental Immunology, 1975, 21, 109-14.	2.6	112
123	Studies on the terminal stages of complement lysis. Immunology, 1973, 24, 135-45.	4.4	54
124	The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology, 1973, 24, 259-75.	4.4	136
125	Studies on antigenic competition. II. Abolition of antigenic competition by antibody against or tolerance to the dominant antigen: a model for antigenic competition. Immunology, 1972, 22, 185-97.	4.4	43
126	The purification of specific antibody as F(ab′)2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry, 1971, 8, 81-88.	1.2	54

#	Article	IF	CITATIONS
127	REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS. Journal of Experimental Medicine, 1970, 131, 629-641.	8.5	200
128	REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS. Journal of Experimental Medicine, 1970, 131, 643-657.	8.5	263
129	Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology, 1970, 19, 983-6.	4.4	54
130	The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clinical and Experimental Immunology, 1968, 3, 447-55.	2.6	44
131	The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. Journal of Immunology, 1968, 100, 691-8.	0.8	163
132	An estimate of some molecular parameters of bovine conglutinin. Immunochemistry, 1964, 1, 37-41.	1.2	13
133	THE LOCALIZATION OF IN VIVO BOUND COMPLEMENT IN TISSUE SECTIONS. Journal of Experimental Medicine, 1962, 115, 63-82.	8.5	255
134	An attempt to characterize the lupus erythematosus cell antigen. Immunology, 1961, 4, 153-63.	4.4	28